Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases.
Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases.
复制标题
19009年大流行在神经炎症性疾病中的表现和影响。
DOI：
10.1002/acn3.51314
复制
发表时间：
2021-04
影响因子：
5.3
通讯作者：
Multiple Sclerosis Resilience to COVID-19 (MSReCOV) Collaborative
中科院分区：
文献类型：
--
作者：
Levin SN;Venkatesh S;Nelson KE;Li Y;Aguerre I;Zhu W;Masown K;Rimmer KT;Diaconu CI;Onomichi KB;Leavitt VM;Levine LL;Strauss-Farber R;Vargas WS;Banwell B;Bar-Or A;Berger JR;Goodman AD;Longbrake EE;Oh J;Weinstock-Guttman B;Thakur KT;Edwards KR;Riley CS;Xia Z;De Jager PL;Multiple Sclerosis Resilience to COVID-19 (MSReCOV) Collaborative
报告一项计划中的多中心、为期一年的前瞻性研究的初步结果，该研究旨在检查COVID-19在神经炎性疾病（NID）患者（尤其是多发性硬化症（MS）患者）中的风险和影响。于2020年4月，我们向家居环境中的个人发放在线问卷，以评估NID（PwNID）患者中疑似COVID-19的患病率和潜在风险因素，以及他们的神经护理变化。截至2020年4月30日，我们的队列包括1115名参与者（630名NID，98% MS; 485名参考）。202名（18%）居住在COVID-19高患病率地区的参与者符合2020年4月CDC疑似COVID-19的症状标准，但由于检测短缺，只有4%的参与者接受了检测。在所有参与者中，那些疑似COVID-19的人更年轻，种族更多样化，并且报告了更多的抑郁症和肝病。PwNID与参考组的疑似COVID-19发生率相同。疾病管理的早期变化包括21%的远程医疗就诊和9%的PwNID治疗变化。在调整潜在混杂因素后，神经功能障碍的增加与疑似COVID-19的可能性增加相关（ORadj = 1.45，1.17-1.84）。我们对COVID-19大流行期间患者报告的真实的经验的研究补充了医生报告的MS病例登记，这些病例记录了过量的严重病例。总体而言，PwNID疑似COVID-19的风险与参考人群相似。
To report initial results of a planned multicenter year‐long prospective study examining the risk and impact of COVID‐19 among persons with neuroinflammatory disorders (NID), particularly multiple sclerosis (MS). In April 2020, we deployed online questionnaires to individuals in their home environment to assess the prevalence and potential risk factors of suspected COVID‐19 in persons with NID (PwNID) and change in their neurological care. Our cohort included 1115 participants (630 NID, 98% MS; 485 reference) as of 30 April 2020. 202 (18%) participants, residing in areas with high COVID‐19 case prevalence, met the April 2020 CDC symptom criteria for suspected COVID‐19, but only 4% of all participants received testing given testing shortages. Among all participants, those with suspected COVID‐19 were younger, more racially diverse, and reported more depression and liver disease. PwNID had the same rate of suspected COVID‐19 as the reference group. Early changes in disease management included telemedicine visits in 21% and treatment changes in 9% of PwNID. After adjusting for potential confounders, increasing neurological disability was associated with a greater likelihood of suspected COVID‐19 (ORadj = 1.45, 1.17–1.84). Our study of real‐time, patient‐reported experience during the COVID‐19 pandemic complements physician‐reported MS case registries which capture an excess of severe cases. Overall, PwNID seem to have a risk of suspected COVID‐19 similar to the reference population.
登录
查看更多内容
影响因子：
2.6
作者：
Learmonth YC;Motl RW;Sandroff BM;Pula JH;Cadavid D
通讯作者：
Cadavid D
影响因子：
3.7
作者：
Bove, Riley;Secor, Elizabeth;De Jager, Philip L.
通讯作者：
De Jager, Philip L.
影响因子：
56.9
作者：
Kissler, Stephen M.;Tedijanto, Christine;Lipsitch, Marc
通讯作者：
Lipsitch, Marc
DOI：
10.1212/nxi.0000000000000505
发表时间：
2018-11-01
影响因子：
8.8
作者：
Bove, Riley;Garcha, Priya;Gelfand, Jeffrey M.
通讯作者：
Gelfand, Jeffrey M.
影响因子：
1.3
作者：
Balto, Julia M.;Pilutti, Lara A.;Motl, Robert W.
通讯作者：
Motl, Robert W.